HeartWare International — Technical Presentation (October 2011)
32 slides from HeartWare International's technical presentation, Oct 3, 2011
Slide 1: Results of the HeartWare ADVANCE Bridge to Transplant Trial and CAP Update
Results of the HeartWare ADVANCE Bridge to Transplant Trial and CAP Update MS Slaughter, K Aaronson, S Najjar, E McGee, F Pagani, I Gregoric, O.H Frazier, E Birks, T Icenogle, V Jeevanandam, M Acker, R John, A Rongione and the Advance Investigators October 2, 2011
Slide 2: Disclosures
Disclosures Study PI and training site for HeartWare, Inc. Grant support Thoratec Corp. DSMB Novo Nordisk HVAD is still investigational in the U.S.
Slide 3: Reminder: data are an update from ADVANCE BTT and CAP
Reminder: The data presented today constitute an update from the Advance BTT Trial and Continuing Access Protocol (CAP) in the U. S. Results, including adverse events and outcomes, could possibly change in the future as the trial reaches completion. Data cut-off July 15, 2011 Database lock August 25
Slide 4: HeartWare Ventricular Assist System
HeartWare Ventricular Assist System HVAD miniaturized implantable blood pump About the size of a "D" battery Provides up to 10 L/min of flow Centrifugal design, continuous flow Hybrid magnetic / hydrodynamic impeller suspension Optimizes flow, pump surface washing, and hemocompatibility Thin (4.2 mm
Slide 5: Unique Features of the HVAD Pump
Unique Features of the HVAD Pump Accurate flow estimation Log files enable flow and power waveform analysis Novel impeller design enables excellent hemodynamics No abdominal surgery or pump pocket Fits in the pericardial space Anatomically fits smaller patients Less surgery; potentially minimizes bl
Slide 6: Apical Sewing Ring
Apical Sewing Ring Apical Sewing Ring
Slide 7: HVAD Implant
HVAD Implant HVAD Implant
Slide 8: Outflow Graft
Outflow Graft Outflow Graft
Slide 9: Outflow Graft
Outflow Graft Outflow Graft
Slide 10: ADVANCE Trial Design
Multi-site (30), prospective trial to evaluate the HeartWare HVAD as a bridge-to-transplant in the US Enrollment period was August 2008 to February 2010 All patients were followed for ^ 180 days following implant or until cardiac transplantation, device explant for recovery or death Treatment group
Slide 11: Results from Pivotal ADVANCE BTT Trial
Results from Pivotal ADVANCE BTT Trial Enrolled: 140 patients, Completed: February 28, 2010 Study cohort "Success" was 92% Non-inferiority to INTERMACS control group (p < 0.0001) Overall survival was 94% at 180 days and 91% at 360 days 30-day mortality was 1.4% Favorable adverse event profile compar
Slide 12: Continued Access Protocol (CAP) for ADVANCE Trial
Continued Access Protocol (CAP) for ADVANCE Trial CAP for the bridge-to-transplant indication was approved for the 30 sites that enrolled at least 1 patient in ADVANCE The same enrollment protocol is in effect for CAP 3 allotments of additional patients (54, 54 and 94) have been granted by the FDA f
Slide 13: Baseline Characteristics ADVANCE/CAP
Baseline Characteristic BTT and CAP (N = 241) BTT (N = 140) CAP (N = 101) Age (years) 52.7 +- 11.7 53.3 +- 10.3 52.0 +- 13.5 Male sex (%) 169 (70) 101 (72) 68 (67) Race [number (%)] White Black/African American Hispanic/Other 166 (69) 63 (26) 12 (5) 101 (72) 32 (23) 7 (5) 65 (64) 31 (31) 5 (5) Body-
Slide 14: Baseline Characteristics ADVANCE/CAP (continued)
Baseline Characteristic BTT and CAP (N = 241) BTT (N = 140) CAP (N = 101) Arterial blood pressure (mmHg) Systolic Diastolic Mean 103.8 +- 15.2 63.5 +- 10.7 76.6 +- 11.2 103.3 +- 15.6 63.7 +- 11.2 76.2 +- 12.1 104.3 +- 14.7 63.2 +- 10.1 77.2 +- 9.8 Cardiac index (liters/min/m2) 2.1 +- 0.7 2.1 +- 0.6
Slide 15: INTERMACS Classification and Survival
INTERMACS Classification ADVANCE and CAP Patients (%) % Survival (to 6 mo. endpoint) INTERMACS 1 8 (3.3) 100 INTERMACS 2 76 (31.5) 91 INTERMACS 3 108 (44.8) 94 INTERMACS 4-7 48 (19.9) 94 *One patient missing INTERMACS profile pre-Implant (still alive)
Slide 16: Adverse Events
% Patients Affected Event Rate (per patient-year) Infections Driveline exit 11.6 0.19 Sepsis 10.4 0.14 Respiratory dysfunction 22.8 0.36 Arrhythmia Ventricular 22.4 0.33 Supraventricular 22.8 0.34 Right heart failure Inotropes or inhaled NO 29.0 0.25 RVAD 3.3 0.04 Renal dysfunction 10.4 0.14 Hepatic
Slide 17: Adverse Events (continued)
% Patients Affected Event Rate (per patient-year) Bleeding requiring re-op 11.6 0.16 Device exchanges Procedure-related 1.2 0.01 Suspected thrombus 4.1 0.05 Other 1.7 0.02 Neurological events Ischemic CVA ICVA ^ 48 hours 2.9 0.03 ICVA > 48 hours 5.0 0.07 Hemorrhagic CVA 5.4 0.06 TIA 3.7 0.05 Adverse
Slide 18: Adjustment in Anticoagulation Patterns
(CHART) Adjustment in Anticoagulation Patterns Median INR = 2.2 Median INR = 1.7 *Adjustment on March 15, 2011: maintaining INR in recommended 2.0-3.0 range and starting ASA at 325 mg/day versus 81 mg/day
Slide 19: Reduction in Pump Exchange for Suspected Thrombus
(CHART) Patients implanted up to January 15, 2011 Reduction in Pump Exchange for Suspected Thrombus
Slide 20: Strokes: Post-Discharge Analysis
Strokes: Post-Discharge Analysis (CHART) - Minimum 6 months from implant - 67% of ICVA patients Modified Rankin Score 2 or lower - 80% ICVA Survival / Transplanted at 180 days
Slide 21: Perioperative Ischemic Strokes (<48 Hours)
Perioperative Ischemic Strokes (<48 Hours) (CHART) 140 patients 101 patients
Slide 22: GI Bleeding
GI Bleeding (n = 241) Day 30: 96.2% Day 90: 93.6% Day 180: 92.0% Day 360: 88.7%
Slide 23: Freedom from Sepsis
Freedom from Sepsis (n = 241) Day 30: 96.7% Day 90: 95.8% Day 180: 91.5% Day 360: 86.8%
Slide 24: Freedom from Driveline Infections
Freedom from Driveline Infections Day 30: 97.5% Day 90: 96.6% Day 180: 91.4% Day 360: 86.6%
Slide 25: Slide 25
Slide 26: Causes of Death for ADVANCE and CAP
Causes of Death for ADVANCE and CAP Causes Number of Patients Intracerebral Bleeding 7 Multisystem Organ Failure 6 Sepsis 5 Right Heart Failure 2 Undetermined 2 Respiratory Failure 1 Liver Failure 1 Renal Failure 1 Myocardial Infarction 1 Hemorrhagic Shock 1 Controller failure 1 Brain tumor 1
Slide 27: Improvements in 6-Minute Walk
Improvements in 6-Minute Walk (CHART) p < 0.0001
Slide 28: Survival for ADVANCE and CAP
Survival for ADVANCE and CAP (n = 241) Survival 30 days 98% 90 days 97% 180 days 93% 360 days 86%
Slide 29: BTT and CAP Patient Outcomes
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 0 60 120 180 240 300 360 Group Patients at Risk HVAD 241 225 194 172 128 107 84 Days Post Implant Proportion of Patients 71.4% Alive on Device 21.6% Transplanted* 7.1% Death BTT and CAP Patients (n = 241) 92.9% Transplanted or Alive * includes one patient
Slide 30: HVAD
HVAD HVAD
Slide 31: HVAD sintered inflow
HVAD sintered inflow HVAD sintered inflow
Slide 32: Summary
Summary 241 patients have been enrolled in ADVANCE and CAP with at least 6 months of follow up for 207 patient-years of support. Average duration of support: 313 days. Survival remains high at 92.7% at 180 days despite lower transplant rate than in prior BTT trials. Reoperations for bleeding as well
HeartWare International — Technical Presentation (October 2011) on 6ix